Viridian Therapeutics
NASDAQ · VRDN·Waltham, MA·Mid-cap·Phase 3
Clinical-stage biopharma developing veligrotug (anti-IGF-1R) and VRDN-003 (subcutaneous IGF-1R) for thyroid eye disease (TED). Veligrotug Phase 3 THRIVE/THRIVE-2 positive results, BLA-bound; VRDN-003 in Phase 3 REVEAL.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Viridian Corporate Deck March 2026 (REVEAL Update) | Corporate overview | March 30, 2026 | 62 |